Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.37 |
| ▸ | NPC1 | O15118 | 7/20 | 0.37 |
| ▸ | RAB9A | P51151 | 7/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.34 |
| ▸ | RELA | Q04206 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL3535197 | 0.94 | ALDH1A1 (0.36) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3537885 | 0.83 | ALDH1A1 (0.34) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13314825 | 0.83 | ALDH1A1 (0.34) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3535201 | 0.82 | ALDH1A1 (0.36) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| Bromide SCHEMBL3538791 | 0.82 | ALDH1A1 (0.33) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3543197 | 0.79 | TMIGD3 (0.38) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13314864 | 0.79 | TMIGD3 (0.38) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3536883 | 0.77 | OPRM1 (0.43) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL13314823 | 0.77 | OPRM1 (0.43) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL3537276 | 0.77 | PDK1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | claimed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | claimed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| EP-1608662-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083218-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | ALDH1A1 1895/4885NPC1 3023/4885RAB9A 4051/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 4570/4885NPC1 1533/4885RAB9A 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.